Metformin effects on cholesterol levels
Pro Research Analysisby 
Searched over 200M research papers
Metformin and Cholesterol Levels: Effects and Mechanisms
Metformin’s Impact on Total and LDL Cholesterol
Multiple studies consistently show that metformin lowers total cholesterol and LDL cholesterol levels. In non-diabetic adults, metformin significantly reduces both total cholesterol and LDL-c, though the effect on HDL-c and triglycerides is generally not significant 25. In patients with type 2 diabetes, metformin also leads to small but significant reductions in total and LDL cholesterol, independent of its glucose-lowering effects . Similar cholesterol-lowering effects have been observed in patients with combined hyperlipidemia, where metformin caused a dose-dependent decrease in total and LDL cholesterol, with no significant changes in HDL cholesterol or triglycerides .
Effects in Special Populations: PCOS and Coronary Artery Disease
In women with polycystic ovary syndrome (PCOS), metformin may have a more pronounced effect on triglyceride levels, and when combined with omega-3 supplements, it can further reduce cholesterol and increase HDL levels compared to metformin alone 210. In patients with coronary artery disease but without diabetes, adding metformin to statin therapy further decreases LDL cholesterol and PCSK9 levels, helping more patients reach recommended LDL targets .
Mechanisms Behind Cholesterol Reduction
Metformin’s cholesterol-lowering effects are linked to several biological pathways:
- AMPK Activation: Metformin activates AMP-activated protein kinase (AMPK), which suppresses cholesterol synthesis by downregulating SREBP-2 and its target proteins, while upregulating LDL receptors, leading to increased clearance of LDL cholesterol from the blood 67.
- PCSK9 Inhibition: Metformin reduces the expression of PCSK9, a protein that limits the number of LDL receptors. Lower PCSK9 levels mean more LDL receptors are available to clear LDL cholesterol, further reducing blood cholesterol 34.
- ChREBP Pathway: Metformin inhibits the carbohydrate-responsive element-binding protein (ChREBP), which in turn reduces PCSK9 expression and enhances LDL receptor activity, creating a link between glucose and cholesterol metabolism .
- Metabolite Changes: Metformin decreases certain phosphatidylcholine metabolites, which is associated with lower LDL cholesterol levels and may contribute to cardiovascular protection .
- Cholesterol Efflux: Metformin may promote cholesterol removal from macrophages by upregulating FGF21, which increases the expression of cholesterol transporters (ABCA1 and ABCG1), potentially reducing atherosclerotic plaque formation .
Effects on HDL Cholesterol and Triglycerides
Most studies find that metformin does not significantly affect HDL cholesterol or triglyceride levels in the general population 125. However, in specific groups such as women with PCOS, metformin may help lower triglycerides, especially when combined with other therapies 210.
Summary of Clinical Findings
- Metformin consistently lowers total and LDL cholesterol in both diabetic and non-diabetic individuals 1256.
- The reductions in cholesterol are generally modest but may contribute to cardiovascular risk reduction 56.
- The effect on HDL cholesterol and triglycerides is minimal in most populations, with some exceptions in PCOS 210.
- Metformin’s cholesterol-lowering actions are mediated by AMPK activation, PCSK9 inhibition, and enhanced cholesterol efflux 34678.
Conclusion
Metformin provides a modest but consistent reduction in total and LDL cholesterol levels, independent of its glucose-lowering effects. These benefits are seen in both diabetic and non-diabetic populations and are mediated by several molecular pathways that regulate cholesterol metabolism. While its effects on HDL cholesterol and triglycerides are limited, metformin’s cholesterol-lowering properties may contribute to its overall cardiovascular protective effects.
Sources and full results
Most relevant research papers on this topic